NTV Asset Management LLC Acquires 61,443 Shares of CRISPR Therapeutics AG $CRSP

Key Points

• NTV Asset Management acquired 61,443 shares of CRISPR Therapeutics worth approximately $3.4 million, while institutional investors and hedge funds collectively own 69.2% of the company.
• Analyst sentiment remains cautiously positive: CRSP has a consensus “Moderate Buy” rating and an average price target of $65.75, though ratings range from Strong Buy to Sell.
• CRSP shares opened at $49.39, below their 50-day and 200-day moving averages. The company reported a quarterly loss of $0.94 per share and insiders have sold roughly $4.9 million of stock over the past 90 days.

NTV Asset Management LLC acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 61,443 shares of the company's stock, valued at approximately $3,399,000. NTV Asset Management LLC owned approximately 0.06% of CRISPR Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of CRSP. Sterling Capital Management LLC increased its stake in shares of CRISPR Therapeutics by 15.5% in the third quarter. Sterling Capital Management LLC now owns 1,934 shares of the company's stock valued at $107,000 after buying an additional 260 shares in the last quarter. Versant Capital Management Inc raised its holdings in shares of CRISPR Therapeutics by 175.1% in the second quarter. Versant Capital Management Inc now owns 465 shares of the company's stock valued at $25,000 after buying an additional 296 shares during the last quarter. Sunbelt Securities Inc. raised its holdings in shares of CRISPR Therapeutics by 4.5% in the first quarter. Sunbelt Securities Inc. now owns 7,843 shares of the company's stock valued at $373,000 after buying an additional 336 shares during the last quarter. Axxcess Wealth Management LLC raised its holdings in shares of CRISPR Therapeutics by 2.5% in the third quarter. Axxcess Wealth Management LLC now owns 14,464 shares of the company's stock valued at $800,000 after buying an additional 350 shares during the last quarter. Finally, D.A. Davidson & CO. lifted its position in CRISPR Therapeutics by 5.9% during the 1st quarter. D.A. Davidson & CO. now owns 6,324 shares of the company's stock worth $301,000 after buying an additional 353 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

Analyst Ratings Changes

CRSP has been the topic of a number of research analyst reports. HC Wainwright reissued a "buy" rating on shares of CRISPR Therapeutics in a report on Friday, October 9th. Weiss Ratings restated a "sell (d-)" rating on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. Wall Street Zen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Finally, UBS Group initiated coverage on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. They set a "neutral" rating and a $52.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $65.75.

CRISPR Therapeutics Stock Down 1.2%

Shares of CRSP opened at $49.39 on Friday. The business's fifty day moving average price is $54.60 and its two-hundred day moving average price is $53.28. The firm has a market capitalization of $4.78 billion, a price-to-earnings ratio of -10.38 and a beta of 1.76. CRISPR Therapeutics AG has a 52 week low of $44.12 and a 52 week high of $68.71. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. The firm had revenue of $10.18 million for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. On average, analysts predict that CRISPR Therapeutics AG will post -4.44 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In related news, Director Ali Behbahani sold 13,679 shares of the firm's stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $57.09, for a total value of $780,934.11. Following the transaction, the director owned 16,637 shares in the company, valued at $949,806.33. This trade represents a 45.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 10,400 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $60.24, for a total value of $626,496.00. Following the completion of the sale, the general counsel owned 94,784 shares of the company's stock, valued at approximately $5,709,788.16. The trade was a 9.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 93,558 shares of company stock worth $4,881,663 in the last ninety days. 5.20% of the stock is currently owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG NASDAQ: CRSP is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company's research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.